DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Andrew Kelly - 1 Stephanos Bibas - 1 Ross ’ - 1 Ross - 1 Thomson - 1 Bibas - 1 Blake Brittain - 1 David Bario - 1
Top related locs:
Square , New York U.S Delaware Washington
Top related orgs:
Thomson Reuters - 1 REUTERS - 1 Ross Intelligence - 1 U.S - 1 Circuit - 1 Tech - 1 Meta - 1 Microsoft - 1

Search resuls for: "Stephanos Bibas"


2 mentions found


☆ Thomson Reuters AI copyright dispute must go to trial, judge says
  + stars: | 2023-09-26 | by ( Blake Brittain | Thomson Reuters | Blake Brittain Reports On Intellectual Property Law | ) www.reuters.com   time to read: +3 min
Circuit Judge Stephanos Bibas sets the stage for what could be one of the first trials related to the unauthorized use of data to train AI systems. "This case continues to be about Ross’ theft of Thomson Reuters proprietary commentary, analysis, and organizational system," the spokesperson said. Thomson Reuters' 2020 lawsuit accused legal research company Ross Intelligence of copying Westlaw's "headnotes," which summarize points of law in court opinions. Thomson Reuters accused Ross of misusing thousands of the headnotes to train its AI-based legal search engine. Bibas also said he could not decide whether a ruling for Ross or Thomson Reuters would best serve the public interest.
Persons: Andrew Kelly, Stephanos Bibas, Ross ’, Ross, Thomson, Bibas, Blake Brittain, David Bario, Lisa Shumaker Organizations: Thomson Reuters, REUTERS, Ross Intelligence, U.S, Circuit, Tech, Meta, Microsoft, Reuters, Thomson Locations: Square , New York, U.S, Delaware, Washington
☆ Drugmakers prevail in dispute over U.S. discount drug program
  + stars: | 2023-01-30 | by ( Brendan Pierson | Thomson Reuters | Brendan Pierson Reports On Product Liability Litigation | ) www.reuters.com   time to read: +2 min
Jan 30 (Reuters) - Drug manufacturers can limit healthcare providers' use of outside pharmacies for dispensing drugs under a federal drug discount program, a federal appeals court ruled Monday. The case centers on the federal 340B program, in which drugmakers provide discounts to eligible healthcare providers that serve low-income populations. Drugmakers are required to participate in the 340B program in order to receive funds from government health insurance programs like Medicare and Medicaid. Sanofi, Novo Nordisk and AstraZeneca all continued to allow 340B providers without in-house pharmacies to use a single contract pharmacy. HHS ordered them to stop, saying the new policies were not allowed under the 340B program.
0 next >>
Total: 2